Bone markers in polycystic ovary syndrome : a multicentre study
Lingaiah, Shilpa; Morin‐Papunen, Laure; Piltonen, Terhi; Puurunen, Johanna; Sundström‐Poromaa, Inger; Stener‐Victorin, Elisabet; Bloigu, Risto; Risteli, Juha; Tapanainen, Juha S. (2017-08-28)
Lingaiah, S., Morin-Papunen, L., Piltonen, T., Puurunen, J., Sundström-Poromaa, I., Stener-Victorin, E., … Tapanainen, J. S. (2017). Bone markers in polycystic ovary syndrome: A multicentre study. Clinical Endocrinology, 87(6), 673–679. https://doi.org/10.1111/cen.13456
© 2017 John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Lingaiah, S., Morin-Papunen, L., Piltonen, T., Puurunen, J., Sundström-Poromaa, I., Stener-Victorin, E., … Tapanainen, J. S. (2017). Bone markers in polycystic ovary syndrome: A multicentre study. Clinical Endocrinology, 87(6), 673–679. https://doi.org/10.1111/cen.13456, which has been published in final form at https://doi.org/10.1111/cen.13456. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
https://rightsstatements.org/vocab/InC/1.0/
https://urn.fi/URN:NBN:fi-fe2019082725783
Tiivistelmä
Abstract
Objective: Hyperandrogenism, hyperinsulinaemia and obesity, known characteristics of polycystic ovary syndrome (PCOS), may influence bone mineral density and biochemical markers of bone turnover (BTMs) can provide a noninvasive assessment of bone turnover. To this end, the serum concentrations of BTMs and 25‐hydroxyvitamin D (25OHD) were analysed in women with PCOS, and their possible associations with metabolic parameters of PCOS were determined.
Subjects and methods: Bone formation markers procollagen type I amino‐terminal propeptide (PINP) and osteocalcin (OC), and bone resorption marker carboxy‐terminal cross‐linking telopeptide of type I collagen (CTX), along with 25OHD, were measured in 298 women with PCOS and 194 healthy controls.
Results: Serum levels of PINP (47.0 ± 20.2 vs 58.1 ± 28.6 μg/L, P < .001) and OC (18.2 ± 7.5 vs 20.6 ± 9.8 μg/L, P < .001) were decreased in women with PCOS compared with controls, whereas no significant differences were found in CTX and 25OHD levels. Age‐stratified analyses suggested that PINP (50.5 ± 21.7 vs 68.2 ± 26.6 μg/L, P < .001) and OC levels (20.4 ± 7.6 vs 25.5 ± 9.6 μg/L,P < .001) were decreased only in the younger age group (≤30 years) women with PCOS compared with controls. The formation markers and resorption marker decreased with age in both study groups.
Conclusions: Bone formation markers were decreased in younger women with PCOS when compared with healthy women, which may affect bone mass in these women.
Kokoelmat
- Avoin saatavuus [37559]